ARWR vs. PODD

In the year-to-date period, ARWR achieves a -36.44% return, which is significantly lower than PODD's 22.85% return. Over the past 10 years, ARWR has underperformed PODD with an annualized return of 12.00%, while PODD has yielded a comparatively higher 19.42% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and Insulet Corporation (PODD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARWR Sharpe Ratio is -0.47, which is lower than the PODD Sharpe Ratio of 0.75. The chart below compares the historical Sharpe Ratios of ARWR and PODD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ARWR nor PODD has paid dividends to shareholders.

The maximum ARWR drawdown since its inception was -99.83%, which is greater than PODD's maximum drawdown of -90.28%. Use the drawdown chart below to compare losses from any high point for ARWR and PODD. For additional features, visit the drawdowns tool.

Arrowhead Pharmaceuticals, Inc. (ARWR) has a higher volatility of 31.59% compared to Insulet Corporation (PODD) at 6.97%. This indicates that ARWR's price experiences larger fluctuations and is considered to be riskier than PODD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Arrowhead Pharmaceuticals, Inc. and Insulet Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.